Den europeiske union - italiensk - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ipilimumab - melanoma; carcinoma, renal cell; carcinoma, non-small-cell lung; mesothelioma, malignant; colorectal neoplasms - agenti antineoplastici - melanomayervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.  yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. relative to nivolumab monotherapy, an increase in progression-free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression (see sections 4. 4 e 5. renal cell carcinoma (rcc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5. non-small cell lung cancer (nsclc)yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. malignant pleural mesothelioma (mpm)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5. oesophageal squamous cell carcinoma (oscc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.

Den europeiske union - italiensk - EMA (European Medicines Agency)

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - agenti antineoplastici - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.

Sveits - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - ipilimumabum - concentrato per soluzione per infusione - ipilimumabum 50 mg, trometamoli hydrochloridum, natrii chloridum, mannitolum, acidum penteticum, polysorbatum 80, natrii hydroxidum aut acidum hydrochloridum, aqua ad iniectabile q.s. ad solutionem pro 10 ml corresp. natrium 23 mg. - melanoma, carcinoma a cellule renali, kolorektales carcinoma - biotechnologika

Sveits - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - ipilimumabum - concentrato per soluzione per infusione - ipilimumabum 200 mg, trometamoli hydrochloridum, natrii chloridum, mannitolum, acidum penteticum, polysorbatum 80, natrii hydroxidum aut acidum hydrochloridum, aqua ad iniectabile q.s. ad solutionem pro 40 ml corresp. natrium 92 mg. - melanoma, carcinoma a cellule renali, kolorektales carcinoma - biotechnologika

Sveits - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

ipsen pharma schweiz gmbh - cabozantinibum - compresse rivestite con film - cabozantinibum 20 mg ut cabozantinibi l-malas 25.34 mg, cellulosum microcristallinum, lactosum 15.54 mg, hydroxypropylcellulosum, carmellosum natricum conexum corresp. natrium 0.9 mg, silica colloidalis anhydrica, magnesii stearas, Überzug: hypromellosum, triacetinum, e 171, e 172 (flavum), pro compresso obducto. - nierenzellkarzinom, leberzellkarzinom, schilddrüsenkarzinom - synthetika

Sveits - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

ipsen pharma schweiz gmbh - cabozantinibum - compresse rivestite con film - cabozantinibum 40 mg ut cabozantinibi l-malas 50.69 mg, cellulosum microcristallinum, lactosum 31.07 mg, hydroxypropylcellulosum, carmellosum natricum conexum corresp. natrium 1.8 mg, silica colloidalis anhydrica, magnesii stearas, Überzug: hypromellosum, triacetinum, e 171, e 172 (flavum), pro compresso obducto. - nierenzellkarzinom, leberzellkarzinom, schilddrüsenkarzinom - synthetika

Sveits - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

ipsen pharma schweiz gmbh - cabozantinibum, natrium - compresse rivestite con film - cabozantinibum 60 mg ut cabozantinibi l-malas 76.03 mg, cellulosum microcristallinum, lactosum 46.61 mg, hydroxypropylcellulosum, carmellosum natricum conexum corresp. natrium 2.7 mg, silica colloidalis anhydrica, magnesii stearas, Überzug: hypromellosum, triacetinum, e 171, e 172 (flavum), pro compresso obducto. - nierenzellkarzinom, leberzellkarzinom, schilddrüsenkarzinom - synthetika

Sveits - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

merck (schweiz) ag - avelumabum - concentrato per soluzione per infusione - avelumabum 200 mg, mannitolum, acidum aceticum glaciale, polysorbatum 20, natrii hydroxidum corresp. natrium 1.725 mg, aqua ad iniectabile q.s. ad solutionem pro 10 ml. - merkelzellkarzinom - biotechnologika